Journal
MEDICINAL RESEARCH REVIEWS
Volume -, Issue -, Pages -Publisher
WILEY
DOI: 10.1002/med.21973
Keywords
blood-brain barrier; drug delivery; multiple sclerosis; precision medicine; stem cell therapy
Categories
Ask authors/readers for more resources
Multiple sclerosis is a chronic demyelinating disease, and current FDA-approved disease-modifying therapeutics can only alleviate the disease progression. Systemic drug administration may not be effective for therapeutic targets in the central nervous system. Therefore, alternative drug delivery strategies that improve drug accumulation in the brain should be considered for patients with rapidly progressing disease.
Multiple sclerosis is a chronic demyelinating disease with different disease phenotypes. The current FDA-approved disease-modifying therapeutics (DMTs) cannot cure the disease, but only alleviate the disease progression. While the majority of patients respond well to treatment, some of them are suffering from rapid progression. Current drug delivery strategies include the oral, intravenous, subdermal, and intramuscular routes, so these drugs are delivered systemically, which is appropriate when the therapeutic targets are peripheral. However, the potential benefits may be diminished when these targets sequester behind the barriers of the central nervous system. Moreover, systemic drug administration is plagued with adverse effects, sometimes severe. In this context, it is prudent to consider other drug delivery strategies improving their accumulation in the brain, thus providing better prospects for patients with rapidly progressing disease course. These targeted drug delivery strategies may also reduce the severity of systemic adverse effects. Here, we discuss the possibilities and indications for reconsideration of drug delivery routes (especially for those non-responding patients) and the search for alternative drug delivery strategies. More targeted drug delivery strategies sometimes require quite invasive procedures, but the potential therapeutic benefits and reduction of adverse effects could outweigh the risks. We characterized the major FDA-approved DMTs focusing on their therapeutic mechanism and the potential benefits of improving the accumulation of these drugs in the brain.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available